Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Sanofi’s CAD Therapy Sutimlimab Up for PAFSC Review on June 2
May 20, 2022
- Orphan Tag for Pfizer’s Gene Therapy Up for Panel Review on June 1
May 20, 2022
- Investigation of COVID-19 Jab Disposals Not on the Table at This Time: Health Minister
May 20, 2022
- LDP Pharma Study Group to Push Price Maintenance for Patented Meds, Rethink of “Off-Year” Re-Pricing towards Honebuto
May 20, 2022
- LDP Social Security Execs Leery of Macroeconomic Indexing
May 20, 2022
- Chuikyo OKs Listing of 14 Drugs on May 25, Biggest Peak Sales Forecast for Vabysmo
May 19, 2022
- Japan Govt Promulgates Economic Security Law
May 19, 2022
- Cabometyx Likely to Escape CEA Scheme Unscathed with No Price Cut
May 19, 2022
- 4 Drugs Face Zero Premium Rule for Low Cost Disclosures: May Price Listing
May 19, 2022
- Impact of Annual Price Revisions on Pharma Industry Hard to Gauge Comprehensively: Govt
May 19, 2022
- Cabinet Adopts Ordinance for Emergency Approval, COVID Drugs Subject to New System
May 18, 2022
- 2022 Honebuto Outline Calls for “Planned Investment” Towards a New Capitalism
May 18, 2022
- Dupixent Faces Second Re-Pricing in August with 11.7% Cut
May 18, 2022
- Taiho’s GIST Med Pimitespib, Cabotegravir/Rilpivirine Combo Use Up for PAFSC Review on May 30
May 18, 2022
- MHLW Panels Again Find No Significant Concerns over Safety of COVID-19 Vaccines
May 17, 2022
- Janssen’s COVID-19 Vaccine Up for MHLW Panel Review on May 30
May 17, 2022
- MHLW Orders Label Revisions for Dexamethasone, Betamethasone to Warn of Phaeochromocytoma Crisis
May 16, 2022
- 5 New Probable Cases of Acute Pediatric Hepatitis Found in Japan
May 16, 2022
- Japan Clears Bill to Create Emergency Approval System, Enforcement Slated by Month-End
May 13, 2022
- Health Minister Vows Thorough Discussions on Drug Pricing, Mentions Policy Veterans’ Proposals
May 13, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…